Bank Of America Corp Tango Therapeutics, Inc. Transaction History

Bank Of America Corp

$1.19 Trillion
Q3 2024

A detailed history of Bank Of America Corp transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 175,369 shares of TNGX stock, worth $715,505. This represents 0.0% of its overall portfolio holdings.

Number of Shares

175,369

Previous 81,900 114.13%

Holding current value

$715,505

Previous $702,000 92.31%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$7.36 - $11.93 $687,931 - $1.12 Million	93,469 Added 114.13%	175,369 $1.35 Million
Q2 2024 Aug 14, 2024	SELL	$6.66 - $10.15 $174,112 - $265,351	-26,143 Reduced 24.2%	81,900 $702,000
Q1 2024 May 15, 2024	BUY	$7.51 - $12.88 $362,334 - $621,421	48,247 Added 80.69%	108,043 $857,000
Q4 2023 Feb 14, 2024	SELL	$6.52 - $12.01 $34,158 - $62,920	-5,239 Reduced 8.06%	59,796 $591,000
Q2 2023 Aug 14, 2023	SELL	$2.67 - $4.7 $92,734 - $163,240	-34,732 Reduced 34.81%	65,035 $215,000
Q1 2023 May 12, 2023	SELL	$3.76 - $8.06 $179,024 - $383,760	-47,613 Reduced 32.31%	99,767 $394,000
Q4 2022 Feb 10, 2023	BUY	$3.41 - $8.29 $174,667 - $424,630	51,222 Added 53.27%	147,380 $1.07 Million
Q3 2022 Nov 14, 2022	BUY	$3.25 - $5.46 $51,070 - $85,798	15,714 Added 19.53%	96,158 $348,000
Q2 2022 Aug 12, 2022	BUY	$3.86 - $8.01 $2,095 - $4,349	543 Added 0.68%	80,444 $364,000
Q1 2022 May 16, 2022	SELL	$7.01 - $10.94 $97,978 - $152,908	-13,977 Reduced 14.89%	79,901 $606,000
Q4 2021 Feb 08, 2022	BUY	$9.55 - $14.29 $896,248 - $1.34 Million	93,848 Added 312826.66%	93,878 $1.03 Million
Q3 2021 Nov 15, 2021	BUY	$9.56 - $17.3 $286 - $519	30 New	30 $0

Others Institutions Holding TNGX

# of Institutions

123

Shares Held

91.7M

Call Options Held

3.1K

Put Options Held

1.5K

View Full List

About Tango Therapeutics, Inc.

Ticker TNGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,067,296
Market Cap $359M
Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...

More about TNGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Tango Therapeutics, Inc. Transaction History